Clinical validation of the Lilly SP‐X P‐tau217 assay: Performance in underrepresented cohorts
The Lilly SP-X p-tau217 assay showed strong concordance with amyloid PET in total cohort and underrepresented groups.Assay performance is in line with guidance from the Global CEOi on AD Working Group.Data support the clinical utility of the assay in multiple cohorts to aid in AD diagnosis.
Authors
- Andrew E. Schade
- Adam Abel
- Rose Beck (ORCID: https://orcid.org/0000-0001-5581-8561)
- Michael E. Hodsdon
- Antonio Chambers
- Emily C. Collins
- Amanda Sheffield Morris (ORCID: https://orcid.org/0000-0003-3587-822X)
- Michael J. Pontecorvo (ORCID: https://orcid.org/0000-0002-8419-7589)
- Mark A. Mintun
- Samantha C. Burnham (ORCID: https://orcid.org/0000-0003-4805-5193)
- Ming‐Chi Lu (ORCID: https://orcid.org/0000-0001-9051-0351)
- Heinz Reiske
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
- Published
- 2025-06-29
- DOI
- https://doi.org/10.1002/dad2.70139
- Citations
- 2
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Eli Lilly and Company